Metagenomix, Inc. was founded by Yale scientists Mike Snyder (co-founder of Affomix with ESV), his PhD student, Elias Theodorou, and ESV to develop methods to screen for pharmacological activity the metabolites of bacteria which cannot be cultured in the laboratory. The company was established in 2010, with seed financing lead by ESV alongside co-investor Connecticut Innovations. Greg Gardiner served as the CEO and chairman; Mike Sherman served on the board, with Rob Bettigole as a board observer.